Related Experiment Video
Updated: Dec 5, 2025

Granulocyte-dependent Autoantibody-induced Skin Blistering
Published on: October 12, 2012
Cutaneous Vasculitis During Secukinumab Treatment
Camila da Silva Cendon Duran1, Mittermayer Barreto Santiago2,3,4
1Hospital das Clínicas da Universidade de São Paulo, São Paulo, Brazil.
Abstract:
Secukinumab is an inhibitor of interleukin IL-17A, and is mainly used in the treatment of psoriasis, psoriatic arthritis and ankylosing spondylitis. Although rarely, this drug may induce paradoxical reactions, such as cutaneous vasculitis. Worldwide, only four previous cases of vasculitis induced by secukinumab have been reported. We herein report the first case described in Brazil of cutaneous vasculitis due to secukinumab in a patient with peripheral spondyloarthritis who demonstrated good resolution after withdrawal of the drug and initiation of etanercept. Clinicians should be aware of this rare but potentially serious adverse effect of secukinumab.
Learning Points:
Treatment with biologics can cause vasculitis.The vasculitis may be independent of class of the biologic.Only five cases of vasculitis induced by secukinumab have been reported.
Related Concept Videos
Endocarditis II: Clinical Features of Infective Endocarditis
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Nephrotic Syndrome II : Assessment and Medical Management
Venous Thrombosis IV: Nursing Management

